CD274 and non-small cell lung carcinoma: In recent years, blockade of the PD-1/PD-L1 immune checkpoint has not only transformed the treatment of patients with advanced NSCLC but has also made significant inroads into the therapeutic landscape of patients with early-stage disease1–14.